Real-World tofacitinib study in ulcerative colitis ends early
NCT ID NCT05069259
First seen Jan 11, 2026 · Last updated Jun 19, 2026 · Updated 30 times
Summary
This study looked at how well the drug tofacitinib (Xeljanz) works for people with moderate to severe ulcerative colitis in everyday medical practice in Switzerland. It measured symptom improvement and gut inflammation using stool samples. The study was small with 18 participants and was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Fribourgeois de Gastroenterologie
Fribourg, Switzerland
-
Clarunis, Universitätsspital
Basel, Switzerland
-
Kantonsspital Baselland
Liestal, Switzerland
-
Kantonsspital St, Gallen
Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
-
Verein IBD Study Group
Bern, CH - 3012, Switzerland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tofacitinib (Xeljanz)
What this could lead to
If successful, this study could confirm that tofacitinib works well in everyday practice for people with ulcerative colitis, helping doctors make better treatment decisions.
What could go wrong
This was a small, terminated study with only 18 participants, so results may not be reliable or apply to everyone. Tofacitinib also carries risks like infections and blood clots.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.